Morgan Stanley Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics (NASDAQ:DNLI) had its price objective hoisted by equities research analysts at Morgan Stanley from $40.00 to $42.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price objective indicates a potential upside of 131.28% from the stock’s previous close.

Several other equities analysts also recently issued reports on DNLI. Jefferies Financial Group reissued a “buy” rating and issued a $40.00 target price on shares of Denali Therapeutics in a research report on Monday, March 2nd. HC Wainwright lifted their price target on Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday. Robert W. Baird increased their price objective on Denali Therapeutics from $29.00 to $32.00 and gave the company an “outperform” rating in a report on Thursday. Stifel Nicolaus raised their price objective on Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Wolfe Research assumed coverage on Denali Therapeutics in a report on Monday, February 23rd. They set a “peer perform” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.82.

Denali Therapeutics Stock Down 8.0%

NASDAQ:DNLI opened at $18.16 on Thursday. The company has a market cap of $2.88 billion, a PE ratio of -6.11 and a beta of 1.02. Denali Therapeutics has a twelve month low of $10.57 and a twelve month high of $23.77. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $20.43 and its two-hundred day moving average is $17.83.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same quarter in the previous year, the firm posted ($0.67) earnings per share. Analysts anticipate that Denali Therapeutics will post -2.71 EPS for the current year.

Insiders Place Their Bets

In other Denali Therapeutics news, insider Alexander O. Schuth sold 17,218 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $284,097.00. Following the sale, the insider directly owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. This trade represents a 5.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the transaction, the chief executive officer owned 296,833 shares of the company’s stock, valued at $4,897,744.50. The trade was a 10.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 12.50% of the company’s stock.

Institutional Trading of Denali Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC purchased a new position in Denali Therapeutics during the second quarter valued at approximately $26,000. Johnson Financial Group Inc. purchased a new stake in Denali Therapeutics in the 3rd quarter worth approximately $29,000. State of Wyoming purchased a new stake in Denali Therapeutics in the 2nd quarter worth approximately $29,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Denali Therapeutics during the 4th quarter worth approximately $57,000. Finally, Quarry LP acquired a new stake in shares of Denali Therapeutics during the 3rd quarter worth approximately $64,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA approval of AVLAYAH — AVLAYAH received FDA approval as a brain‑targeting therapy for Hunter syndrome, giving Denali its first approved commercial asset and creating a clear commercialization pathway. Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• Positive Sentiment: Morgan Stanley raised its price target to $42 and kept an overweight rating — a large revision implying ~131% upside vs. the current price, signaling strong sell‑side confidence post‑approval. Benzinga
• Positive Sentiment: Goldman Sachs raised its target to $40 and reiterated a buy — another high target reflecting elevated expectations for AVLAYAH’s commercial prospects. Benzinga
• Positive Sentiment: Stifel, BTIG, HC Wainwright, Robert W. Baird also raised targets and/or ratings — most moved targets into the $32–$42 range and maintained buy/outperform views, adding upward pressure on the stock. (Sources include Benzinga and TickerReport.) Benzinga TickerReport
• Neutral Sentiment: Company discussion/transcript on commercial launch plans — management provided details on launch timing, supply and go‑to‑market strategy in a call/transcript, helping investors assess execution risk but not immediately changing fundamentals. Denali Discusses FDA Approval and Commercial Launch Plans for AVLAYAH (Transcript)
• Neutral Sentiment: Wider media coverage — outlets (MSN, Business Insider, Seeking Alpha) reported the FDA approval and will likely broaden investor and clinician awareness; coverage supports sentiment but execution and uptake remain the next items to watch. MSN Business Insider

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.